Incidence and predictors of pulmonary toxicity in japanese patients receiving low-dose amiodarone

Circulation Journal

Volumn 71, Issue 10, 2007, Pages 1610-1616

  Yamada, Yuichiro ^a   Shiga, Tsuyoshi ^a   Matsuda, Naoki ^a   Hagiwara, Nobuhisa ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Amiodarone; Carbon monoxide; Diffusion capacity; KL 6; Pulmonary; Toxicity

Indexed keywords

AMIODARONE; CARBON MONOXIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART VENTRICLE TACHYCARDIA; HUMAN; JAPANESE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG FUNCTION TEST; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; RISK ASSESSMENT; SCREENING TEST; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION;

ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CA-15-3 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; JAPAN; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TACHYCARDIA;

EID: 34948851934     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1610     Document Type: Article

References (33)

1. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
2. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations. Am J Cardiol 1999; 84: 37R-45R.
3. Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. Am Heart J 1983; 106: 906-915.
4. Vorperian VR, Havighurst TC, Millrer S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
5. Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: A review of the risks and recommendations for surveillance. Can J Cardiol 2000; 16: 1435-1440.
6. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin HT, Wyndham CR. Amiodarone pulmonary toxicity: Prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988; 12: 781-788.
7. Endoh Y, Hanai R, Uto K, Tanaka T, Ohta Y, Kasanuki H, et al. Diagnostic accuracy of KL-6 as a marker of amiodarone-induced pulmonary toxicity. Pacing Clin Electrophysiol 2000; 23: 2010-2013.
8. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity: Recognition and pathogenesis: Part I. Chest 1988; 93: 1067-1075.
9. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-59.
10. Fraire AE, Guntupalli KK, Greenberg SD, Cartwright J Jr, Chasen MH. Amiodarone pulmonary toxicity: A multidisciplinary review of current status. South Med J 1993; 86: 67-77.
11. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM, Stohler JL. Safety and efficacy of amiodarone: The low-dose perspective. Chest 1988; 93: 54-59.
12. Singh SN, Fisher SG, Deedwania PC, Rohatgi P, Singh BN, Fletcher RD, for the Congestive Heart Failure-Survival Trial of Antiarrythmic Therapy (CHF-STAT) Investigators. Pulmonary effect of amiodarone in patients with heart failure. J Am Coll Cardiol 1997; 30: 514-517.
13. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation 1993; 88: 764-768.
14. Ott MC, Khoor A, Leventhal JP, Paterick TE, Burger CD. Pulmonary toxicity in patients receiving low-dose amiodarone. Chest 2003; 123: 646-651.
15. Satomi K, Kurita T, Takatsuki S, Yokoyama Y, Chinushi M, Tsuboi N, et al. Amiodarone therapy in patients implanted with cardioverter-defibrillator for life-threatening ventricular arrhythmias. Circ J 2006; 70: 977-984.
16. Shiga T, Wakaumi M, Imai T, Suzuki T, Hosaka F, Yamada Y, et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure. Circ J 2002; 66: 600-604.
17. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Efficacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51.
18. Fung RCY, Chan WK, Chu CM, Yue CS. Low dose amiodarone-induced lung injury. Int J Cardiol 2006; 113: 144-145.
19. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004; 363: 461.
20. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
21. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 3492-3494.
22. Kato T, Nishio K. Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology 2006; 11: 693-698.
23. Martin II WJ. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 131-138.
24. Kennedy JI, Myers JL, Plumb VJ, Fulmer JD. Amiodarone-associated pulmonary toxicity: A clinical and pathologic correlations. Arch Intern Med 1987; 147: 50-55.
25. Baritussio A, Marzini S, Agostini M, Alberti A, Cimenti C, Bruttomesso D, et al. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1189-L1199.
26. Bargout R, Jankov A, Dincer E, Wang R, Komodromos T, Ibarra-Sunga O, et al. Amiodarone induceds apoptosis of human and rat alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2001; 278: L1039-L1044.
27. Quaglino D, Huy Riem Ha HR, Duner E, Bruttomesso D, Bigler L, Follath F, et al. Effects of metabolites and analogs of amiodarone on alveolar macrophages: Structure-activity relationship. Am J Physiol Lung Cell Mol Physiol 2004; 287: L438-L447.
28. Kudenchuk PJ, Pierson DJ, Green HL, Graham EL, Sears GK, Trobaugh GB. Prospective evaluation of amiodarone pulmonary toxicity. Chest 1984; 86: 541-548.
29. Ohar JA, Jackson F, Redd RM, Evans GR, Bedrossian CW. Usefulness of serial pulmonary function testing as an indicator of amiodarone toxicity. Am J Cardiol 1989; 64: 1322-1326.
30. Gleadhill IC, Wise RA, Schonfeld SA, Scott PP, Guarnieri T, Levine JH, et al. Serial lung function testing in patients treated with amiodarone: A prospective study. Am J Med 1989; 86: 4-10.
31. Rembold CM. Number needed to screen: Development of a statistic for disease screening. BMJ 1998; 317: 307-312.
32. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamamoto M, Akiyama M. New serum indicator of interstitial pneumonitis activity: Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
33. Ohnishi H, Yokoyama A, Yasuhara Y, Watanabe A, Naka T, Hamada H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003; 58: 872-875.